Additionally, the increased tumorigenicity observed in response to AGK-mediated downregulation of FOXO1 in breast cancer may be due to aberrant activation of AKT [15], which is a major downstream effector of the EGFR [27, 28]. This evidence concerns the gene EGFR and breast carcinoma.